IMARC Group has recently released a report titled “Sarcopenia Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)” that presents a comprehensive assessment of the sarcopenia market. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market size, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets, and recent advancements in the global market. It also sheds light on crucial segments and market drivers, along with challenges faced by industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the sarcopenia market.
Sarcopenia represents a medical condition characterized by the progressive loss of strength, muscle mass, and function that occurs as a natural part of the aging process. It is often caused by a misalignment of signals for muscle cell growth and breakdown, resulting in decreased quality of life, fractures, falls, and disability. Some of the common symptoms of sarcopenia are muscle weakness. Individuals suffering from this condition may also experience loss of stamina, difficulty performing daily activities, trouble climbing stairs, poor balance and falls, a decrease in muscle size, etc. The diagnosis of the ailment is based on a review of the patient’s medical history, clinical features, and physical exam.
Request a Free Sample Report: https://www.imarcgroup.com/sarcopenia-market/requestsample
The expanding geriatric population, which is prone to changes in the number and size of muscle fibers, is primarily augmenting the sarcopenia market. In addition to this, the increasing incidences of several associated risk factors, including inadequate protein intake, sedentary lifestyle, obesity, hormonal imbalance, neurological disorders, etc., are further stimulating the market growth. Moreover, the emerging popularity of effective medications, such as β-hydroxy β-methyl butyrate, which acts as a signaling molecule to improve protein synthesis and prevent loss of lean body mass, is acting as another significant growth-inducing factor.
Apart from this, the rising adoption of bioelectrical impedance analysis for diagnosing the disease on account of its several benefits, including minimal invasion, portability, ease of use, relatively low cost, safety, etc., is also bolstering the market growth. Additionally, the escalating utilization of resistance and strength training to treat the condition by stimulating muscle protein synthesis and supporting muscular strength is offering lucrative growth opportunities to the market. Besides this, the increasing usage of myostatin inhibitors that can promote healthy muscle mass and enhance mobility in patients is projected to fuel the sarcopenia market over the forecasted period.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the sarcopenia market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the sarcopenia market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/sarcopenia-market
Key Questions Answered in this Report:
- How has the sarcopenia market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the sarcopenia market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the sarcopenia market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Browse the Latest Research Report:
Bunion Market Report 2023-2033
Bulimia Nervosa Market Report 2023-2033
Cancer Pain Market Report 2023-2033
Blepharitis Market Report 2023-2033
How This Report Can Help You:
- The report on sarcopenia market presents a comprehensive overview and analysis of the epidemiology and market for this condition in the seven major markets (7MM): the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- With insights into both current and emerging therapies in the 7MM, this report offers valuable information for businesses seeking to understand trends and opportunities within the sarcopenia market.
- The sarcopenia market report covers historical and forecasted market data, including epidemiology scenario, providing a reliable and informative resource for developing effective business strategies in 7MM.
- Our report on the sarcopenia market can help businesses stay abreast of the trends and drivers, gain a competitive edge and drive success.
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
